|
1
|
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
|
Blood
|
2011
|
2.23
|
|
2
|
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
|
Drug Resist Updat
|
2009
|
1.47
|
|
3
|
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
|
Blood
|
2010
|
1.32
|
|
4
|
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
|
Mol Cancer Ther
|
2008
|
1.23
|
|
5
|
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
|
Blood
|
2008
|
1.09
|
|
6
|
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
|
J Biol Chem
|
2012
|
1.06
|
|
7
|
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
|
Genes Cancer
|
2012
|
1.05
|
|
8
|
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
|
Blood
|
2008
|
1.01
|
|
9
|
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
|
Mol Cancer Ther
|
2010
|
0.84
|
|
10
|
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
|
PLoS One
|
2011
|
0.84
|
|
11
|
Investigation of design space for freeze-drying: use of modeling for primary drying segment of a freeze-drying cycle.
|
AAPS PharmSciTech
|
2011
|
0.81
|